Absence of the association with CC chemokine receptor 5 polymorphism in polymyalgia rheumatica

C. Salvarani, L. Boiardi, J. M. Timms, T. Silvestri, A. Ranzi, P. L. Macchioni, L. Pulsatelli, L. S. Di Giovine

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective. Elevated RANTES serum levels are present in polymyalgia rheumatica (PMR) patients with active disease. Chemokines may contribute to the inflammatory PMR process through their binding to CC chemokine receptor 5 (CCR5). The aim of this study was to examine if the 32 base pair deletion allele in CCR5 (CCR5Δ32 allele) might be associated with PMR susceptibility and influence the disease outcome. Methods. We enrolled 88 consecutive patients with PMR residing in the Reggio Emilia area (Italy) who had a follow-up duration of at least one year. As a control group we used 86 healthy blood donors from the same geographic area. The CCR5 genotype of all PMR patients and controls was studied by polymerase chain reaction amplification of the region which includes the 32 deletion (CCR5Δ32). RANTES serum levels were measured by commercial ELISA kits in CCR5Δ32 heterozygous and CCR5 homozygous PMR patients at diagnosis before starting corticosteroid therapy and again after 6 months of therapy, as well as in 28 healthy subjects over 50 years of age. Results. Frequencies of the CCR5 and CCR5Δ32 alleles in patients and controls did not differ significantly. Homozygosity for CCR5Δ32 was not detected in PMR patients and was detected in only one of the controls. No significant differences were observed between the patients carrying the CCR5Δ32 allele and those homozygous for the normal CCR5 allele when we compared sex, presence of distal synovitis and systemic signs and/or symptoms, initial and cumulative prednisone dose, duration of therapy, ESR at diagnosis, frequency of relapse/recurrence and RANTES serum levels at diagnosis and after 6 months of corticosteroids. Conclusion. These results indicate that the frequency of the 32 deletion of the CCR5 receptor was not significantly different between PMR patients and healthy controls, and this genotype does not appear to be associated with the susceptibility to or severity of PMR.

Original languageEnglish
Pages (from-to)591-595
Number of pages5
JournalClinical and Experimental Rheumatology
Volume18
Issue number5
Publication statusPublished - 2000

Fingerprint

CCR5 Receptors
Polymyalgia Rheumatica
Chemokine CCL5
Alleles
Adrenal Cortex Hormones
Serum
Genotype
Recurrence
Synovitis
Disease Susceptibility
Prednisone
Blood Donors
Chemokines
Base Pairing
Italy
Signs and Symptoms
Healthy Volunteers
Therapeutics
Enzyme-Linked Immunosorbent Assay

Keywords

  • CCR5 polymorphism
  • Polymyalgia rheumatica
  • Relapse/recurrence

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Salvarani, C., Boiardi, L., Timms, J. M., Silvestri, T., Ranzi, A., Macchioni, P. L., ... Di Giovine, L. S. (2000). Absence of the association with CC chemokine receptor 5 polymorphism in polymyalgia rheumatica. Clinical and Experimental Rheumatology, 18(5), 591-595.

Absence of the association with CC chemokine receptor 5 polymorphism in polymyalgia rheumatica. / Salvarani, C.; Boiardi, L.; Timms, J. M.; Silvestri, T.; Ranzi, A.; Macchioni, P. L.; Pulsatelli, L.; Di Giovine, L. S.

In: Clinical and Experimental Rheumatology, Vol. 18, No. 5, 2000, p. 591-595.

Research output: Contribution to journalArticle

Salvarani, C, Boiardi, L, Timms, JM, Silvestri, T, Ranzi, A, Macchioni, PL, Pulsatelli, L & Di Giovine, LS 2000, 'Absence of the association with CC chemokine receptor 5 polymorphism in polymyalgia rheumatica', Clinical and Experimental Rheumatology, vol. 18, no. 5, pp. 591-595.
Salvarani, C. ; Boiardi, L. ; Timms, J. M. ; Silvestri, T. ; Ranzi, A. ; Macchioni, P. L. ; Pulsatelli, L. ; Di Giovine, L. S. / Absence of the association with CC chemokine receptor 5 polymorphism in polymyalgia rheumatica. In: Clinical and Experimental Rheumatology. 2000 ; Vol. 18, No. 5. pp. 591-595.
@article{cf528f19ece249a0a5fa0397d4fde84b,
title = "Absence of the association with CC chemokine receptor 5 polymorphism in polymyalgia rheumatica",
abstract = "Objective. Elevated RANTES serum levels are present in polymyalgia rheumatica (PMR) patients with active disease. Chemokines may contribute to the inflammatory PMR process through their binding to CC chemokine receptor 5 (CCR5). The aim of this study was to examine if the 32 base pair deletion allele in CCR5 (CCR5Δ32 allele) might be associated with PMR susceptibility and influence the disease outcome. Methods. We enrolled 88 consecutive patients with PMR residing in the Reggio Emilia area (Italy) who had a follow-up duration of at least one year. As a control group we used 86 healthy blood donors from the same geographic area. The CCR5 genotype of all PMR patients and controls was studied by polymerase chain reaction amplification of the region which includes the 32 deletion (CCR5Δ32). RANTES serum levels were measured by commercial ELISA kits in CCR5Δ32 heterozygous and CCR5 homozygous PMR patients at diagnosis before starting corticosteroid therapy and again after 6 months of therapy, as well as in 28 healthy subjects over 50 years of age. Results. Frequencies of the CCR5 and CCR5Δ32 alleles in patients and controls did not differ significantly. Homozygosity for CCR5Δ32 was not detected in PMR patients and was detected in only one of the controls. No significant differences were observed between the patients carrying the CCR5Δ32 allele and those homozygous for the normal CCR5 allele when we compared sex, presence of distal synovitis and systemic signs and/or symptoms, initial and cumulative prednisone dose, duration of therapy, ESR at diagnosis, frequency of relapse/recurrence and RANTES serum levels at diagnosis and after 6 months of corticosteroids. Conclusion. These results indicate that the frequency of the 32 deletion of the CCR5 receptor was not significantly different between PMR patients and healthy controls, and this genotype does not appear to be associated with the susceptibility to or severity of PMR.",
keywords = "CCR5 polymorphism, Polymyalgia rheumatica, Relapse/recurrence",
author = "C. Salvarani and L. Boiardi and Timms, {J. M.} and T. Silvestri and A. Ranzi and Macchioni, {P. L.} and L. Pulsatelli and {Di Giovine}, {L. S.}",
year = "2000",
language = "English",
volume = "18",
pages = "591--595",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "5",

}

TY - JOUR

T1 - Absence of the association with CC chemokine receptor 5 polymorphism in polymyalgia rheumatica

AU - Salvarani, C.

AU - Boiardi, L.

AU - Timms, J. M.

AU - Silvestri, T.

AU - Ranzi, A.

AU - Macchioni, P. L.

AU - Pulsatelli, L.

AU - Di Giovine, L. S.

PY - 2000

Y1 - 2000

N2 - Objective. Elevated RANTES serum levels are present in polymyalgia rheumatica (PMR) patients with active disease. Chemokines may contribute to the inflammatory PMR process through their binding to CC chemokine receptor 5 (CCR5). The aim of this study was to examine if the 32 base pair deletion allele in CCR5 (CCR5Δ32 allele) might be associated with PMR susceptibility and influence the disease outcome. Methods. We enrolled 88 consecutive patients with PMR residing in the Reggio Emilia area (Italy) who had a follow-up duration of at least one year. As a control group we used 86 healthy blood donors from the same geographic area. The CCR5 genotype of all PMR patients and controls was studied by polymerase chain reaction amplification of the region which includes the 32 deletion (CCR5Δ32). RANTES serum levels were measured by commercial ELISA kits in CCR5Δ32 heterozygous and CCR5 homozygous PMR patients at diagnosis before starting corticosteroid therapy and again after 6 months of therapy, as well as in 28 healthy subjects over 50 years of age. Results. Frequencies of the CCR5 and CCR5Δ32 alleles in patients and controls did not differ significantly. Homozygosity for CCR5Δ32 was not detected in PMR patients and was detected in only one of the controls. No significant differences were observed between the patients carrying the CCR5Δ32 allele and those homozygous for the normal CCR5 allele when we compared sex, presence of distal synovitis and systemic signs and/or symptoms, initial and cumulative prednisone dose, duration of therapy, ESR at diagnosis, frequency of relapse/recurrence and RANTES serum levels at diagnosis and after 6 months of corticosteroids. Conclusion. These results indicate that the frequency of the 32 deletion of the CCR5 receptor was not significantly different between PMR patients and healthy controls, and this genotype does not appear to be associated with the susceptibility to or severity of PMR.

AB - Objective. Elevated RANTES serum levels are present in polymyalgia rheumatica (PMR) patients with active disease. Chemokines may contribute to the inflammatory PMR process through their binding to CC chemokine receptor 5 (CCR5). The aim of this study was to examine if the 32 base pair deletion allele in CCR5 (CCR5Δ32 allele) might be associated with PMR susceptibility and influence the disease outcome. Methods. We enrolled 88 consecutive patients with PMR residing in the Reggio Emilia area (Italy) who had a follow-up duration of at least one year. As a control group we used 86 healthy blood donors from the same geographic area. The CCR5 genotype of all PMR patients and controls was studied by polymerase chain reaction amplification of the region which includes the 32 deletion (CCR5Δ32). RANTES serum levels were measured by commercial ELISA kits in CCR5Δ32 heterozygous and CCR5 homozygous PMR patients at diagnosis before starting corticosteroid therapy and again after 6 months of therapy, as well as in 28 healthy subjects over 50 years of age. Results. Frequencies of the CCR5 and CCR5Δ32 alleles in patients and controls did not differ significantly. Homozygosity for CCR5Δ32 was not detected in PMR patients and was detected in only one of the controls. No significant differences were observed between the patients carrying the CCR5Δ32 allele and those homozygous for the normal CCR5 allele when we compared sex, presence of distal synovitis and systemic signs and/or symptoms, initial and cumulative prednisone dose, duration of therapy, ESR at diagnosis, frequency of relapse/recurrence and RANTES serum levels at diagnosis and after 6 months of corticosteroids. Conclusion. These results indicate that the frequency of the 32 deletion of the CCR5 receptor was not significantly different between PMR patients and healthy controls, and this genotype does not appear to be associated with the susceptibility to or severity of PMR.

KW - CCR5 polymorphism

KW - Polymyalgia rheumatica

KW - Relapse/recurrence

UR - http://www.scopus.com/inward/record.url?scp=0033813784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033813784&partnerID=8YFLogxK

M3 - Article

C2 - 11072599

AN - SCOPUS:0033813784

VL - 18

SP - 591

EP - 595

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 5

ER -